LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Leukemic Blood Test Has Massive Diagnostic Potential

By LabMedica International staff writers
Posted on 07 Sep 2016
Print article
Image: A photomicrograph of a leukemic cell and an extracellular vesicle (Photo courtesy of University of Manchester).
Image: A photomicrograph of a leukemic cell and an extracellular vesicle (Photo courtesy of University of Manchester).
The potential of a new test, which could revolutionize the way doctors diagnose and monitor common childhood leukemia, has been explored. The test is based on the fact that cancerous acute lymphoblastic leukemia cells produce and release special structures that can be traced in the blood.

The discovery could have major implications on the diagnosis, monitoring, drug delivery and treatment of childhood leukemia. Though there is an 85% to 90% success rate in treatment, children must endure repeat bone marrow biopsies to assess the progress of treatment. This discovery might reduce the frequency of the painful procedures, which can also cause bruising, bleeding and infection.

Scientists at the University of Manchester (UK) and their colleagues have investigated the use of extracellular vesicles, which were thought to be worthless debris, as a diagnostic biomarker. Their presence in the plasma from bone marrow biopsies was discovered their ability to circulate in the blood. The vesicles, which contain the protein actin and have identifiable characteristics of their parent cell, are typified by branching structures. The team also hopes that the vesicles might provide individualized information about the tumors, eventually helping doctors to deliver personalized care.

Suzanne M. Johnson, PhD, the lead author of the study, said, “Our discovery of Extracellular Vesicles could be a game changer in terms of the way we care for children with lymphoblastic leukemia. Our studies have shown that cancerous leukemia cells have the ability to package parts of themselves and then send these structures, the vesicles, to anywhere in the body though the blood. That opens up a world of possibilities in terms of monitoring the progress of the disease and making diagnosis quickly and efficiently. They are also internalized by other cells and act as an effective route for cell communication. Now the challenge is to investigate whether other cancers produce and release these structures as well.” The study was published on July 21, 2016, in the journal Blood.

Related Links:
University of Manchester

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.